楊 慕華

Medicine & Life Sciences

1. Squamous Cell Carcinoma of Head and Neck 100%
2. Head and Neck Neoplasms 77%
3. Neoplasms 69%
4. Neoplasm Metastasis 60%
5. Epithelial-Mesenchymal Transition 58%
6. Squamous Cell Carcinoma 50%
7. Survival 38%
8. Cisplatin 37%
9. Taiwan 36%
10. Colorectal Neoplasms 30%
11. Cetuximab 28%
12. Therapeutics 25%
13. Stomach Neoplasms 24%
14. Neoplastic Stem Cells 23%
15. Drug Therapy 22%
16. Chemoradiotherapy 20%
17. Tumor Microenvironment 18%
18. MicroRNAs 18%
19. Lymphoma, Large B-Cell, Diffuse 18%
20. Snails 18%
21. Catenins 17%
22. Cell Movement 16%
23. Non-Hodgkin's Lymphoma 15%
24. Genes 14%
25. Hypoxia 14%
26. Carcinoma 13%
27. Fluorouracil 13%
28. Nasopharyngeal Carcinoma 13%
29. Recurrence 13%
30. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13%
31. pembrolizumab 13%
32. Hypoxia-Inducible Factor 1 12%
33. Cohort Studies 12%
34. Hepatitis B virus 11%
35. Rituximab 11%
36. Carcinogenesis 11%
37. Mouth 11%
38. Paclitaxel 11%
39. Hepatocellular Carcinoma 11%
40. Neck 11%
41. Breast Neoplasms 10%
42. Induction Chemotherapy 10%
43. Lymph Nodes 10%
44. Radiotherapy 10%
45. Matrix Metalloproteinase 17 10%
46. Lymphoma 10%
47. Population 10%
48. Hematopoietic Stem Cell Transplantation 9%